MAPPING CONFORMATIONAL CHANGES IN GROWTH FACTOR RECEPTRS USING DXMS

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 Dennis Pantazatos被Hixson博士和Quesenberry博士(干细胞生物学科布雷PI)招募到血液和肿瘤科。丹尼斯得到了Divisional和Cobre基金的支持。丹尼斯以优异的成绩在西北大学获得生物医学工程学士学位，在密歇根大学获得人类遗传学硕士学位，并在加州大学圣迭戈分校获得生物医学博士学位。他的博士研究涉及用于蛋白质三维构象分析和蛋白质配基相互作用的氢交换质谱仪(DXMS)。他有出色的发表记录(PNAS、分子药理学、J生物化学、生物化学、膜生物学J)，并且是使用DXMS测定蛋白质结构的专利发明人。丹尼斯将得到全面的项目支持，应用DXMS和图像质谱仪(IMS)来绘制EGFR抑制剂与野生型EGFR或耐受抑制的突变形式结合时构象变化和接触点的差异。他还将开发结合使用DXMS和IMS的体内配基受体相互作用图谱的方法。我们很幸运地招募了丹尼斯，并对利用他在质谱学和蛋白质结构方面的专业知识进行合作研究的潜力感到兴奋。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Dennis Pantazatos was recruited to the Division of Hematology and Oncology by Drs. Hixson and Quesenberry (Division Director, PI on COBRE for Stem Cell Biology). Dennis is supported by both Divisional and COBRE funds. Dennis obtained a BS with honors in biomedical engineering from Northwestern University, an MS in human genetics from the University of Michigan and a PhD in biomedical sciences from UCSD. His PhD research involved the application of deuterium exchange mass spectrometry (DXMS) for protein 3-D conformational analysis and protein ligand interactions. He has an excellent publication record (PNAS, Molecular Pharmacology, J Biological Chemistry, Biochemistry, J of Membrane Biology) and is an inventor on a patent for the use of DXMS for protein structure determinations. Dennis will receive full project support to apply DXMS and image mass spectrometry (IMS) to map the differences in the conformational changes and contact points when an EGFR inhibitor binds to wild type EGFR or mutant forms that are resistant to inhibition. He will also develop methods for mapping ligand receptor interactions in vivo using DXMS in combination with IMS. We feel fortunate to have recruited Dennis and are excited by the potential for collaborative research using his expertise in mass spectrometry and protein structure.